Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

Rubriques :

Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural history study of Stargardt disease SAN DIEGO, Sept. 01, 2024 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel […]

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

financialpost.com - 03/Sep 20:34

VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing...

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

financialpost.com - 03/Sep 20:34

VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing...

Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

drugs.com - 03/Sep 01:09

LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...

Rubriques :

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

Articles similaires

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

Les derniers communiqués